Cardiac safety of formoterol 12 μg twice daily in patients with chronic obstructive pulmonary disease

Pulmonary Pharmacology and Therapeutics

Volumn 20, Issue 5, 2007, Pages 571-579

  Campbell, Sammy C ^a   Criner, Gerard J ^b   Levine, Bernard E ^c   Simon, Stuart J ^d   Smith, Jonathan S ^e   Orevillo, Chadwick J ^f   Ziehmer, Barbara A ^f  

^a UNIVERSITY OF ARIZONA   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Pulmonary Associates   (United States)

^d RADIANT RESEARCH   (United States)

^e NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cardiac safety; COPD; Formoterol

Indexed keywords

FORMOTEROL; PLACEBO;

ADULT; AGED; ARTICLE; BACKACHE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DRY POWDER; ELECTROCARDIOGRAM; FEMALE; GASTROENTERITIS; HEART ATRIUM FLUTTER; HEART RATE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT INTERVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SUPRAVENTRICULAR PREMATURE BEAT; THRUSH; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN;

ADMINISTRATION, INHALATION; AGED; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY, AMBULATORY; ETHANOLAMINES; FEMALE; HUMANS; HYPOTENSION; INFECTION; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; SYNCOPE; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 34447518930     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.06.003     Document Type: Article

References (26)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001;163:1256-76 (updated 2003. Available at http://www.goldcopd.com. Accessed August 4, 2004.
2. Halbert R.J., Isonaka S., George D., and Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease?. Chest 123 (2003) 1684-1692
3. Sullivan S.D., Ramsey S.D., and Lee T.A. The economic burden of COPD. Chest 117 2 Suppl (2000) 5S-9S
4. Tashkin D.P., and Cooper C.B. The role of long-acting bronchodilators in the management of stable COPD. Chest 125 (2004) 249-259
5. Kottakis J., Cioppa G.D., Creemers J., Greefhorst L., Leclerc V., Pistelli R., et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J 9 (2002) 107-115
6. Maesen B.L., Westermann C.J., Duurkens V.A., and van den Bosch J.M. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. Eur Respir J 13 (1999) 1103-1108
7. Celik G., Kayacan O., Beder S., and Durmaz G. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration 66 (1999) 434-439
8. ® Aerolizer™) with salbutamol (Ventodisk™). Respir Med 95 (2001) 817-821
9. Dahl R., Greefhorst L.A., Nowak D., Nonikov V., Byrne A.M., Thomson M.H., et al., for the Formoterol in Chronic Obstructive Pulmonary Disease I (FICOPD I) Study Group. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 778-784
10. Rossi A., Kristufek P., Levine B.E., Thomson M.H., Till D., Kottakis J., et al. For the Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 121 (2002) 1058-1069
11. 2-agonist therapy: a safety review of long-acting agents. Int J Clin Pract 57 (2003) 689-697
12. Salpeter S.R., Ormiston T.M., and Salpeter E.E. Cardiovascular effects of β-agonists in patients with asthma and COPD. A meta-analysis. Chest 125 (2004) 2309-2321
13. Mackstaller L.L., and Alpert J.S. Atrial fibrillation: a review of mechanism, etiology, and therapy. Clin Cardiol 20 (1997) 640-650
14. Naccarelli G.V., Wolbrette D.L., and Luck J.C. Proarrhythmia. Med Clin North Am 85 (2001) 503-526 xii
15. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152 (1995) S77-S121
16. Morganroth J., Borland M., and Chao G. Application of a frequency definition of ventricular proarrhythmia. Am J Cardiol 59 (1987) 97-99
17. Morganroth J., and Horowitz L.N. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 53 (1984) 89B-94B
18. Rutten F.H., Cramer M.J., Grobbee D.E., Sachs A.P., Kirkels J.H., Lammers J.W., et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 26 (2005) 1887-1894
19. Curkendall S.M., DeLuise C., Jones J.K., Lanes S., Stang M.R., Goehring Jr. E., et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 16 (2006) 63-70
20. Huiart L., Ernst P., and Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 128 (2005) 2640-2646
21. Bensch G., Lapidus R.J., Levine B.E., Lumry W., Yegen U., Kiselev P., et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 86 (2001) 19-27
22. ® inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. J Asthma 40 (2003) 505-514
23. Ferguson G.T., Funck-Brentano C., Fischer T., Darken P., and Reisner C. Cardiovascular safety of salmeterol in COPD. Chest 123 (2003) 1817-1824
24. Cazzola M., Imperatore F., Salzillo A., Di Perna F., Calderaro F., Imperatore A., et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 114 (1998) 411-415
25. Au D.H., Udris E.M., Curtis J.R., McDonell M.B., and Fihn S.D. Association between chronic heart failure and inhaled β-2-adrenoceptor agonists. Am Heart J 148 (2004) 915-920
26. Aziz I., McFarlane L.C., and Lipworth B.J. Concomitant inhaled corticosteroid resensitises cardiac beta2-adrenoceptors in the presence of long-acting beta2-agonist therapy. Eur J Clin Pharmacol 54 (1998) 377-381